Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

(2021) Jamy Ard et al.   ADVANCES IN THERAPY

Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?

(2021) Wendy H. Updike et al.   DRUGS

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity

(2021) Mathies M. Jepsen et al.   EXPERT OPINION ON EMERGING DRUGS

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

(2020) Martin Friedrichsen et al.   DIABETES OBESITY & METABOLISM

Semaglutide as a promising antiobesity drug

(2019) Georgios A. Christou et al.   Obesity Reviews

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Newer GLP-1 receptor agonists and obesity-diabetes

(2018) Emily Brown et al.   PEPTIDES

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

(2018) Patrick M O'Neil et al.   LANCET

Pharmacotherapy of obesity: Available medications and drugs under investigation

(2018) Eleni Pilitsi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Anti-Obesity Drugs: A Review about Their Effects and Safety

(2012) Jun Goo Kang et al.   Diabetes & Metabolism Journal